CASTLE BIOSCIENCES INC (CSTL): Price and Financial Metrics
CSTL Price/Volume Stats
| Current price | $19.16 | 52-week high | $26.70 |
| Prev. close | $18.84 | 52-week low | $9.26 |
| Day low | $18.50 | Volume | 41,350 |
| Day high | $19.38 | Avg. volume | 235,661 |
| 50-day MA | $21.62 | Dividend yield | N/A |
| 200-day MA | $19.06 | Market Cap | 525.94M |
CSTL Stock Price Chart Interactive Chart >
CASTLE BIOSCIENCES INC (CSTL) Company Bio
Castle Biosciences, Inc. provides healthcare imaging services. The Company offers diagnostic and prognostic testing solutions for cancers, as well as research and development activities. Castle Biosciences serves customers in the United States.
Latest CSTL News From Around the Web
Below are the latest news stories about CASTLE BIOSCIENCES INC that investors may wish to consider to help them evaluate CSTL as an investment opportunity.
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FRIENDSWOOD, Texas, December 20, 2023--Castle Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4). |
How Much Upside is Left in Castle Biosciences, Inc. (CSTL)? Wall Street Analysts Think 67.01%The mean of analysts' price targets for Castle Biosciences, Inc. (CSTL) points to a 67% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test ResultsFRIENDSWOOD, Texas, December 01, 2023--Castle announced the publication of a new study that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma. |
Castle Biosciences Gains 13%, Insider Trades Reap BenefitLast week, Castle Biosciences, Inc. ( NASDAQ:CSTL ) insiders, who had purchased shares in the previous 12 months were... |
Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual MeetingFRIENDSWOOD, Texas, November 14, 2023--Castle announced that data spanning its dermatologic portfolio of GEP tests was recently presented at the 2023 ASDS Annual Meeting. |
CSTL Price Returns
| 1-mo | -1.03% |
| 3-mo | 0.00% |
| 6-mo | 49.69% |
| 1-year | -18.68% |
| 3-year | -70.50% |
| 5-year | N/A |
| YTD | -11.21% |
| 2023 | -8.33% |
| 2022 | -45.09% |
| 2021 | -36.16% |
| 2020 | 95.37% |
| 2019 | N/A |
Loading social stream, please wait...